MP96-18 IMPACT OF PROSTATE CANCER THERAPY ON URINARY INCONTINENCE AND QUALITY OF LIFE

Abstract

You have accessJournal of UrologyGeneral & Epidemiological Trends & Socioeconomics: Quality Improvement & Patient Safety III1 Apr 2017MP96-18 IMPACT OF PROSTATE CANCER THERAPY ON URINARY INCONTINENCE AND QUALITY OF LIFE Andrew Wang, Paul McClain, and Robert Given Andrew WangAndrew Wang More articles by this author , Paul McClainPaul McClain More articles by this author , and Robert GivenRobert Given More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.3041AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Prostate cancer therapy is known to affect urinary symptoms in men, and its effect on quality of life can depend upon which type of treatment is received. This study is a retrospective review of a large database of men who underwent surgical prostate cancer treatment to assess the impact of therapy on quality of life in prostate cancer patients. METHODS A total of 501 patients who underwent treatment for prostate cancer at a single institution from 2004-2014 were reviewed. The patients in this database were stratified into three groups with respect to the type of therapy received--robot-assisted laparoscopic radical prostatectomy (RLP), brachytherapy, and cryotherapy. Urinary incontinence related quality of life (HRQoL) was assessed at baseline and again at 1-60 months after therapy using the Expanded Prostate Cancer Index Composite (EPIC) questionnaire. Preoperative and postoperative urinary incontinence scores were compared using a Student's t-test. RESULTS Baseline patient characteristics were similar between each treatment group. Diabetes was the only comorbidity correlated with urinary symptoms. Baseline urinary incontinence scores were 93.3, 94.5, and 88.2 in the RLP, brachytherapy, and cryotherapy groups, respectively with a significant difference between the RLP and cryotherapy groups (p = 0.046). Urinary incontinence worsened in all three groups at the first follow-up (2.2 months) after treatment (p < 0.0001). The corresponding scores at long term follow-up were 72.0 (p < 0.0001), 78.1 (p < 0.0001), and 83.1 (p = 0.165). The RLP group urinary incontinence improved over time, while the brachytherapy group incontinence did not change significantly after short term follow-up. Only the cryotherapy group achieved a return to baseline at mean follow-up of 17.3 months. No significant difference was found between mean urinary incontinence for RLP and brachytherapy at long-term follow-up (p = 0.128). CONCLUSIONS Due to the high survival of patients who receive treatment for prostate cancer, quality of life is a major concern when choosing therapy. All three types of prostate cancer treatment studied above cause a short-term worsening of urinary incontinence. Long term, RLP and brachytherapy are associated with worsening of urinary incontinence, whereas cryotherapy is associated with the least impact. Comparatively, RLP and brachytherapy yield similar post-therapy urinary incontinence outcomes. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e1301-e1302 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Andrew Wang More articles by this author Paul McClain More articles by this author Robert Given More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...